Atorvastatin for HAART Suboptimal Responders
Acquired Immune Deficiency Syndrome Virus
About this trial
This is an interventional treatment trial for Acquired Immune Deficiency Syndrome Virus focused on measuring immune activation, antiretroviral therapy, atorvastatin, immune exhaustion, adults, Africa
Eligibility Criteria
List of inclusion Criteria: HIV-infected adults on antiretroviral therapy for at least 6 years with sustained viral suppression (viral load<400 copies), and CD4 increase below 300 cells (difference between current and baseline CD4 count).
List of exclusion Criteria: History of an opportunistic infection within the previous six months, Pregnancy, History of myositis, History of ingestion of lipid-lowering agents at the baseline visit, Use of therapeutic agents known to have substantial drug-drug interactions with statins, and individuals on PI-containing HAART
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
atorvastatin, Lipitor®
Placebo
Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks. Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry
Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry